ENFORTUMAB VEDOTIN-EJFV for Bladder cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 530 adverse event reports in the FDA FAERS database where ENFORTUMAB VEDOTIN-EJFV was used for Bladder cancer.
Most Reported Side Effects for ENFORTUMAB VEDOTIN-EJFV
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 560 | 15.0% | 53 | 172 |
| Malignant neoplasm progression | 410 | 11.0% | 137 | 79 |
| Neuropathy peripheral | 410 | 11.0% | 22 | 61 |
| Fatigue | 281 | 7.5% | 33 | 79 |
| Pruritus | 260 | 7.0% | 25 | 95 |
| Diarrhoea | 257 | 6.9% | 46 | 114 |
| Death | 238 | 6.4% | 238 | 46 |
| Decreased appetite | 230 | 6.2% | 34 | 95 |
| Off label use | 193 | 5.2% | 28 | 48 |
| Alopecia | 185 | 5.0% | 19 | 48 |
| Nausea | 168 | 4.5% | 18 | 79 |
| Skin disorder | 157 | 4.2% | 26 | 80 |
| Pyrexia | 156 | 4.2% | 32 | 94 |
| Hyperglycaemia | 148 | 4.0% | 30 | 77 |
| Taste disorder | 142 | 3.8% | 12 | 40 |
Other Indications for ENFORTUMAB VEDOTIN-EJFV
Transitional cell carcinoma (1,179)
Product used for unknown indication (1,061)
Transitional cell carcinoma metastatic (390)
Ureteric cancer (106)
Malignant neoplasm of renal pelvis (103)
Metastatic carcinoma of the bladder (96)
Bladder transitional cell carcinoma (68)
Transitional cell cancer of the renal pelvis and ureter (58)
Bladder cancer stage iv (24)
Metastases to lymph nodes (23)
Other Drugs Used for Bladder cancer
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (1,279)
PEMBROLIZUMAB (869)
GEMCITABINE (841)
CISPLATIN (780)
NIVOLUMAB (512)
ATEZOLIZUMAB (487)
CARBOPLATIN (332)
BACILLUS CALMETTE-GUERIN ANTIGEN, UNSPECIFIED SUBSTRAIN (326)
GEMCITABINE\GEMCITABINE (240)
ENFORTUMAB VEDOTIN (225)